Table 3.
A review of efficacy estimates for live vaccines (PPT– per protocol; ITT – intention to treat).
| Author (year of publication) | Study design | Type of vaccine | Control | Age of study population | Overall vaccine efficacy (VE) | Lower confidence interval limit (for overall VE) | Upper confidence interval limit (for overall VE) |
|---|---|---|---|---|---|---|---|
| Belshe (1998) |
RCT |
Live |
Placebo |
15-71 months |
0.93 |
0.88 |
0.96 |
| Belshe (2000) |
RCT |
Live |
Placebo |
26-85 months |
0.87 |
0.78 |
0.93 |
| Beutner (1979) |
RCT |
Live |
Placebo |
7-14 years |
0.62 |
0.44 |
0.87 |
| Clover (1991) |
RCT |
Live |
Placebo |
3-18 years |
0.65 |
0.31 |
1.36 |
| Longini (2000) |
RCT |
Live |
Placebo |
15-71 months |
1996-97: 0.90
1997-98: 0.85 |
0.51
0.47 |
1.59
1.53 |
| Neto (2009) |
RCT |
Live |
Placebo |
6 to <36 months |
Year 1, similar antigen: 0.74
Year 1, any antigen: 0.72
Year 2, similar antigen: 0.74
Year 2, any antigen: 0.47 |
0.64
0.62
0.33
0.15 |
0.81
0.80
0.91
0.67 |
| Tam (2007) |
RCT |
Live |
Placebo |
12 to <36 months |
Year 1, PPT, similar antigen: 0.73
Year 1, PPT, any antigen: 0.70
Year 1, ITT, similar antigen: 0.70
Year 1, ITT, any antigen: 0.68
Year 2, PPT, similar antigen: 0.84
Year 2, PPT, any antigen: 0.64 |
0.63
0.61
0.60
0.59
0.70
0.44 |
0.81
0.77
0.78
0.75
0.92
0.77 |
| Vesikari (2006) |
RCT |
Live |
Placebo |
6 to <36 months |
Year 1, PPT, similar antigen: 0.85
Year 1, PPT, any antigen: 0.86
Year 1, ITT, similar antigen: 0.84
Year 1, ITT, any antigen: 0.84
Year 2, PPT, similar antigen: 0.89
Year 2, PPT, any antigen: 0.86
Year 2, ITT, similar antigen: 0.89
Year 2, ITT, any antigen: 0.85 |
0.74
0.76
0.73
0.74
0.82
0.79
0.83
0.78 |
0.92
0.92
0.91
0.90
0.93
0.91
0.93
0.90 |
| Halloran (2003) | Cohort study | Live | No intervention | 1.5-18 years | Combined, A (H1N1) and B: 0.91 | -0.34 | 0.99 |